Theseus Pharmaceuticals, Inc.
THRX · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $36 | $18 | $6 | $4 |
| G&A Expenses | $18 | $9 | $1 | $1 |
| SG&A Expenses | $18 | $9 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $54 | $27 | $7 | $5 |
| Operating Income | -$54 | -$27 | -$7 | -$5 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $3 | $0 | -$5 | -$2 |
| Pre-Tax Income | -$51 | -$27 | -$12 | -$7 |
| Tax Expense | -$4 | $0 | $0 | $0 |
| Net Income | -$47 | -$27 | -$12 | -$7 |
| % Margin | – | – | – | – |
| EPS | -1.22 | -0.76 | -0.47 | -0.28 |
| % Growth | -60.5% | -61.7% | -67.9% | – |
| EPS Diluted | -1.22 | -0.76 | -0.47 | -0.28 |
| Weighted Avg Shares Out | 38 | 36 | 25 | 25 |
| Weighted Avg Shares Out Dil | 38 | 36 | 25 | 25 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$54 | -$27 | -$7 | -$5 |
| % Margin | – | – | – | – |